Malin Corp PLC - investor in life sciences companies - Estimated intrinsic equity value per share at December 31 rises 7.4% to EUR9.34, from EUR8.70 a year earlier. Posts 2022 pretax profit of EUR12.3 million, swinging from loss of EUR3.8 million. "We have made significant progress in supporting our assets towards key milestones and value inflection points, which have catalysed value realisation opportunities," Chief Executive Darragh Lyons says. "As we look to the year ahead, we are confident that our investee companies can continue to progress their innovative technologies and clinical programmes with the aim of advancing important therapies for patients and creating significant value for their stakeholders." In addition, plans to return EUR140 million to shareholders at EUR9.30 per share by way of a tender offer.
"We are delighted to continue to deliver on our long-standing commitment to return the excess capital of the business to our shareholders with this proposed return of up to EUR140 million by way of a tender offer," says Chair Liam Daniel.
Current stock price: EUR7.76
12-month change: up 6.9%
By Eric Cunha, Alliance News news editor
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
